Experts are urging those who have received the Johnson and Johnson vaccine to get the vaccine as soon as possible after a new study shows its effectiveness during the Delta variant flare-up.
An FDA advisory committee unanimously approved the emergency authorization of the J&J booster on Friday, fearing the vaccine might be less effective than the Pfizer or Moderna vaccines. Authorities recommend that anyone who has received the vaccine be given a booster two months later.
“J&J is a very good vaccine. I also think it’s probably a two-shot vaccine, ”Dr. Ashish Jha, dean of the Brown University School of Public Health, told CNN. “It’s really urgent that people get that second hit pretty quickly. “
A new study released Thursday that has yet to be peer reviewed analyzed 620,000 military veterans who received the J&J vaccine this year and found that effective protection fell from 88% in March to just 3% in August .
Vaccine protection has declined among other vaccines as well, but much less dramatically – with Moderna falling from 92% to 64% and Pfizer from 91% to 50% over the same period, according to the study.
“I think anyone who has received a dose of the Johnson & Johnson vaccine may benefit from a second dose of a Johnson & Johnson vaccine,” said Dr Paul Offit, member of the Vaccines and Related Biologics Advisory Committee. the FDA, to CNN’s Jake Tapper. Saturday.
Offit added that if the J&J vaccine had not been rushed for emergency approval, it would likely be a two-shot vaccine.
According to the CDC, more than 15 million Americans have received the J&J vaccine, more than 90% of which were given in the past two months.
The FDA panel on Thursday also unanimously approved the approval of a half-dose booster of Moderna for at-risk Americans who received their second vaccine at least six months ago. “At risk” would apply to adults 65 and over as well as adults 18 and over who may have other health problems, jobs or life situations that put them at greater risk of infection. .
The FDA cleared a Pfizer recall last month for the same risk groups that the panel said should also receive the Moderna recall.